以岭药业 Yiling Pharmaceutical 
石家庄以岭药业股份有限公司(股票代码002603)由中国工程院吴以岭院士创建，在他的领导下，以岭药业始终坚持以科技为先导，以市场为龙头的科技创新发展战略，创立"理论-科研-新药-生产-营销"五位一体的独特运营模式，建立起以中医络病理论创新为指导的新药研发创新技术体系。
在以岭药业的发展历程中，凝聚了一大批科研、管理、生产、营销精英，包括归国专家、外籍专家、博士、硕士及各类高职人才，为河北医科大学培养博士、硕士研究生，被国家人事部批准为博士后科研工作站。

以岭药业以络病理论创新带动中医药产业化，运用现代高新技术研发现代中药、西药、和生物药，研发国家专利新药9个，覆盖心脑血管疾病、感冒呼吸疾病、肿瘤、糖尿病及其并发症等重大疾病领域。通过国家GMP认证的中药生产线、通过欧盟认证的化学制剂生产车间保障了市场供给。以岭药业为国家创新型企业、中国制药工业50 强，以岭商标成为中国驰名商标。国家科技部前领导曾赞誉五位一体的发展模式为"我国中医药科技成果产业化的创举"。

Yiling Pharmaceutical Group, a national level key high and new technology enterprise, is located in Shijiazhuang Hi-tech Development Zone. It was founded by Professor Wu Yiling, a tutor of doctoral students, in 1992.

Under the leadership of Professor Wu, the group company sticks to the principle of promoting the industrialization of TCM with the academic development of TCM, taking technology as the forerunner, market as the guide, and integrating scientific research, clinical practices, production, marketing and teaching together. It applies modern high and new technologies in the research and development of TCMs, western medicines and biologic products and has established modern TCM production lines conforming to GMP standards. It has also constructed a platform with modern characteristics for the research, development and production of TCM as well as modern enterprise management by adopting high and new technologies from both home and abroad.

The group has attracted a group of talented experts for scientific research, medical treatment and production during its development. About 80% of the staff has junior college or higher degrees, among whom more than 200 scientific and technical experts are returned overseas-studied doctors, postdoctors, masters and professionals with assistant senior technical titles or higher. It also enrolls students for doctor degree or master degree together with Hebei Medical University every year and has been approved to be a Postdoctoral Research Station by the Ministry of Personnel. The application of high level talent team as well as high and new technologies and equipment has resulted in outstanding achievements in the research, development and production of TCMs, western medicines and biologic products with modern characteristics.

The group has undertaken and completed numerous national or provincial research projects, including the national 973 Project, the national 863 Project, projects funded by China National New Drug Research and Development Funds, national key projects included in the “Tenth Five-Year Plan”, national high-tech development projects, projects funded by National Natural Science Fund, etc. and has won more than 10 national or provincial prizes for outstanding scientific progresses.

Based on the intrinsic advantages of its organization system, the group has grown into an influential modern pharmaceutical group made up of five major components in China.